Dekkers-founded investment firm Novalis LifeSciences raises $300M for second fund and adds to the team
Two years ago, life sciences VC Novalis LifeSciences announced that it had raised $85 million for its first fund, looking to invest into anywhere between 8 to 12 companies “in various segments of the life science industry.” Novalis now wants to go bigger, announcing earlier this week it raked in $300 million for Novalis LifeSciences Investments II.
The New Hampshire-based VC, founded in 2017 by Ginkgo Bioworks board chairman and ex-Bayer CEO Marijn Dekkers, plans to invest into anywhere between 10 and 15 more life science companies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.